Brokerages Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.74 Per Share
Equities analysts expect Recro Pharma Inc (NASDAQ:REPH) to report earnings of ($0.74) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Recro Pharma’s earnings. Recro Pharma reported earnings per share of ($0.81) during the same quarter last year, which indicates a positive year-over-year growth rate of 8.6%. The company is expected to announce its next quarterly earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full year earnings of ($2.10) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the company will report earnings of ($3.13) per share, with EPS estimates ranging from ($4.31) to ($2.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative return on equity of 60.01% and a negative net margin of 51.88%.
In related news, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $9.27, for a total value of $169,001.37. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 860,414 shares of company stock worth $8,289,916. 21.60% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its position in shares of Recro Pharma by 42.5% during the 3rd quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 7,308 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Recro Pharma by 183.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 14,098 shares in the last quarter. Strs Ohio lifted its position in shares of Recro Pharma by 455.0% during the 4th quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 18,200 shares in the last quarter. Teachers Advisors LLC bought a new position in shares of Recro Pharma during the 2nd quarter worth approximately $162,000. Finally, California State Teachers Retirement System bought a new position in shares of Recro Pharma during the 2nd quarter worth approximately $169,000. 61.83% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Recro Pharma (REPH) traded down $0.39 on Friday, hitting $8.30. The stock had a trading volume of 122,379 shares, compared to its average volume of 116,408. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. The firm has a market cap of $164.69 and a P/E ratio of -3.79. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.59.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.